MarketPulse

inherited retinal diseases

4 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Opus Genetics to Present Phase 3 Presbyopia Data at Major Eye Surgery Conference

Opus Genetics will present three abstracts at ASCRS 2026, including Phase 3 results for phentolamine ophthalmic solution treating presbyopia and mesopic vision issues.
VTRSIRDPhase 3 clinical trialgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Opus Genetics Secures $155M Non-Dilutive Funding to Accelerate Retinal Gene Therapy Pipeline

Opus Genetics secures $155M non-dilutive funding from Oberland Capital, extending cash runway through 2029 and accelerating gene therapy development for inherited retinal diseases.
IRDclinical developmentgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

AAVantgarde Bolsters Leadership with Adverum Veteran Philip Lao as SVP

AAVantgarde Bio names Philip Lao as SVP of Business Development. Lao previously led Adverum's sale to Eli Lilly, bringing pharma expertise from Novartis, Pfizer, and Takeda.
LLYstrategic partnershipsgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Opus Genetics Earns Fast Company Innovation Recognition for Gene Therapy Pipeline

Clinical-stage biotech Opus Genetics named to Fast Company's 2026 most innovative companies list for gene therapy work in inherited retinal diseases.
IRDgene therapybiopharmaceutical